From GlobeNewswire:

Pharvaris announces extraordinary general meeting of shareholders on March 6, 2024, at 12:00 CST to discuss its development of novel oral bradykinin B2 receptor antagonists for treating hereditary angioedema attacks. All relevant documents and meeting information are available on the company’s website and the SEC’s website at www.sec.gov. Pharvaris is a clinical-stage company focused on providing safe and effective alternatives to treat all sub-types of HAE. For more information, you can visit their website at https://pharvaris.com/.

This article announces that Pharvaris will hold an extraordinary general meeting of shareholders on March 6, 2024, at 12:00 CST to discuss its progress in developing novel oral bradykinin B2 receptor antagonists for treating and preventing hereditary angioedema attacks. All the necessary information will be available on the company’s website and the SEC’s website at www.sec.gov. The company aims to provide safe and easy-to-administer alternatives to treat all sub-types of HAE. For more details, you can visit their website at https://pharvaris.com/.



Read more: Pharvaris Announces Extraordinary Meeting of Shareholders